A hospital update finds no evidence that menopause hormone therapy prevents dementia. Understand the findings and their meaning for menopause care.
On October 17, 2026, Melbourne’s Royal Women’s Hospital published an update reporting that evidence reviewed by Professor Martha Hickey’s team did not show that menopausal hormone therapy (MHT) prevents dementia. The hospital connected that finding with guidance against using MHT specifically for dementia prevention.
The announcement reinforces an existing medical position rather than reversing a recommendation to prescribe hormones for dementia prevention. According to the hospital, guidance already advises against using MHT for that purpose. Hickey is the hospital’s Head of Menopause Services and contributed to the World Health Organization’s dementia-prevention guidelines.
That position concerns the purpose of treatment. It is not a blanket judgment on whether MHT may be appropriate for someone’s menopause symptoms or personal circumstances.
Keeping the intended purpose of hormone therapy clear is useful when a discussion moves between present-day concerns and hopes for future health. A treatment decision about current symptoms and a claim about preventing dementia require different supporting evidence.
The hospital’s account sits alongside research examining several related questions: women’s experiences during menopause, performance on cognitive measures and dementia diagnoses later in life. Reading those outcomes separately helps explain why apparently encouraging findings do not automatically change prevention guidance.
The hospital update is a summary of the evidence reviewed, not a detailed publication of the review’s methods and results. It provides no study count, participant total or effect estimates. It also supplies no evidence-certainty ratings or subgroup results for that review. Separate papers with their own numerical findings do not fill those gaps.
The UK Biobank findings are observational associations. As the Medical Xpress report makes clear, they do not establish that MHT caused the difference in dementia diagnoses. A lower relative risk within that study should not be translated into an individual prediction or presented as a treatment benefit. The larger association in the surgical-menopause group carries the same limitation.
The medRxiv preprint also reports observational associations rather than proof of dementia prevention. Its cognitive and imaging findings are not interchangeable with a demonstrated reduction in dementia. Differences involving formulation or APOEε4 status therefore remain research signals, not a basis for selecting a hormone product for brain protection.
For perimenopausal memory and concentration changes, the hospital says both their causes and their possible connection to later-life brain health remain uncertain. Those symptoms should not be equated with dementia. Equally, the absence of evidence for dementia prevention is not proof that MHT has no effect on every aspect of cognition.
These distinctions explain why the reports can coexist without establishing a new preventive use for hormone therapy. They address related questions with different methods and outcomes. The practical task is to match each claim to the evidence behind it rather than treating every brain-health result as an answer to the same question.
For someone troubled by changes in memory or concentration, the useful next conversation is about the changes themselves. The research packet’s practical implication is to describe those concerns to a healthcare professional rather than assuming they are either inevitable menopause symptoms or a forecast of dementia.
That leaves room for a woman’s experience to be taken seriously without deciding its explanation in advance. It also keeps the immediate concern separate from a longer-term prevention claim. Attention to a current difficulty does not require a promise that hormone treatment will protect future brain health.
Questions grounded in this evidence include:
The prevention finding should not be used to dismiss menopause care as a whole. Nor should a possible association in a research report become an additional promised benefit during a treatment discussion. The supported boundary is narrower: available evidence does not justify using MHT specifically to prevent dementia.
For readers sorting broader care questions, placing hormone therapy within the wider range of menopause options provides a separate frame. That conversation can remain centred on personal concerns and circumstances without depending on a dementia-prevention claim.
The Royal Women’s Hospital says women’s experiences have historically been underrepresented in medical research. Hickey’s response is to call for longitudinal studies and clinical trials rather than relying on surveys alone. Following women over time is central to the questions the hospital raises about cognitive experiences and later-life brain health.
This does not make women’s reports less valuable. It places those reports at the beginning of a more complete investigation rather than treating them as a finished explanation. A description of changing concentration can identify an experience that matters. Establishing what it means over time requires a different kind of evidence.
Hickey is also a lead investigator in Wellcome Leap’s CARE program, short for Cutting Alzheimer’s Risk through Endocrinology. The hospital describes it as a US$50 million global research program aiming to cut Alzheimer’s risk for women in half. That is the program’s stated ambition, not an outcome it has already demonstrated.
The direction of this work is therefore broader than asking whether a menopause prescription might offer an extra benefit. It is about building reliable evidence on women’s brain health while keeping current clinical claims within what the research supports.
Going forward, this update should sharpen clinical conversations by taking cognitive concerns seriously while keeping dementia prevention separate from the reasons to prescribe MHT.
Brain-health headlines can make a future possibility sound like a present treatment benefit, so Refemina separates established evidence from emerging claims. For women facing contradictory messages about menopause, its research-led articles offer clear explanations of hormonal transition without treating each concern as a reason for hormone treatment or a supplement.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources